Eli Lilly and Company - Asset Resilience Ratio

Latest as of September 2025: 8.63%

Eli Lilly and Company (LILY34) has an Asset Resilience Ratio of 8.63% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

R$9.91 Billion

≈ $1.95 Billion USD Cash + Short-term Investments

Total Assets

R$114.94 Billion

≈ $22.55 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how Eli Lilly and Company's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Eli Lilly and Company's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	R$9.79 Billion	8.52%
Short-term Investments	R$121.60 Million	0.11%
Total Liquid Assets	R$9.91 Billion	8.63%

Asset Resilience Insights

Limited Liquidity: Eli Lilly and Company maintains only 8.63% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Eli Lilly and Company Industry Peers by Asset Resilience Ratio

Compare Eli Lilly and Company's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Roche Holding AG SW:ROG	Drug Manufacturers - General	15.37%
AstraZeneca PLC F:ZEGA	Drug Manufacturers - General	0.03%
CSPC Pharmaceutical Group Limited F:CVG	Drug Manufacturers - General	4.64%
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd SHE:300357	Drug Manufacturers - General	9.91%
Hangzhou Minsheng Healthcare Co Ltd SHE:301507	Drug Manufacturers - General	24.96%
Firebrick Pharma Ltd AU:FRE	Drug Manufacturers - General	0.29%
Biogen Inc NASDAQ:BIIB	Drug Manufacturers - General	2.74%
Amarin Corporation PLC NASDAQ:AMRN	Drug Manufacturers - General	25.04%

Annual Asset Resilience Ratio for Eli Lilly and Company (2014–2024)

The table below shows the annual Asset Resilience Ratio data for Eli Lilly and Company.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	4.35%	R$3.42 Billion ≈ $671.69 Million	R$78.71 Billion ≈ $15.45 Billion	-0.23pp
2023-12-31	4.57%	R$2.93 Billion ≈ $574.47 Million	R$64.01 Billion ≈ $12.56 Billion	+0.10pp
2022-12-31	4.47%	R$2.21 Billion ≈ $434.00 Million	R$49.49 Billion ≈ $9.71 Billion	-3.54pp
2021-12-31	8.01%	R$3.91 Billion ≈ $766.94 Million	R$48.81 Billion ≈ $9.58 Billion	+0.11pp
2020-12-31	7.89%	R$3.68 Billion ≈ $722.34 Million	R$46.63 Billion ≈ $9.15 Billion	+7.64pp
2019-12-31	0.26%	R$101.00 Million ≈ $19.82 Million	R$39.29 Billion ≈ $7.71 Billion	+0.06pp
2018-12-31	0.20%	R$88.20 Million ≈ $17.31 Million	R$43.91 Billion ≈ $8.62 Billion	-3.13pp
2017-12-31	3.33%	R$1.50 Billion ≈ $293.92 Million	R$44.98 Billion ≈ $8.83 Billion	-0.42pp
2016-12-31	3.75%	R$1.46 Billion ≈ $285.79 Million	R$38.81 Billion ≈ $7.61 Billion	+1.55pp
2015-12-31	2.21%	R$785.40 Million ≈ $154.11 Million	R$35.57 Billion ≈ $6.98 Billion	-0.42pp
2014-12-31	2.63%	R$955.40 Million ≈ $187.47 Million	R$36.31 Billion ≈ $7.12 Billion	--

pp = percentage points

About Eli Lilly and Company

SA:LILY34 Brazil Drug Manufacturers - General

Market Cap

$853.51 Billion

R$4.35 Trillion BRL

Market Cap Rank

#16 Global

#3 in Brazil

Share Price

R$153.70

Change (1 day)

+0.70%

52-Week Range

R$114.19 - R$200.21

All Time High

R$200.21